Tablet bottles for AstraZeneca's cancer medicine Lynparza seen in an undated handout image provided to Reuters on June 27, 2022. AstraZeneca/Handout via REUTERS

Aug 4 (Reuters) - AstraZeneca said on Thursday its drug Lynparza, developed with U.S.-based Merck & Co (MRK.N), was approved by the European Union as an adjuvant treatment for patients with a form of a genetically mutated early-stage breast cancer.

Our Standards: The Thomson Reuters Trust Principles.

Plunging valuations have made biotech companies tempting acquisition targets for cash-rich Big Pharma and a flurry of deals is just what the battered sector needs to turn a corner.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.

Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.

The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.

The industry leader for online information for tax, accounting and finance professionals.

Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.

Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.

Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.